Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from PRISM BioLab Co. LTD ( (JP:206A) ).
PRISM BioLab and Talus Bioscience have announced a collaboration to discover novel inhibitors for transcription factor and protein-protein interaction targets. By integrating PRISM’s chemistry platform with Talus Bio’s AI-guided regulome profiling, the partnership aims to develop first-in-class therapeutics for previously undruggable targets, potentially revolutionizing drug discovery and offering new treatment avenues for complex diseases.
More about PRISM BioLab Co. LTD
PRISM BioLab is a biotechnology company specializing in the discovery and development of small molecule inhibitors targeting protein-protein interactions (PPIs) through its proprietary PepMetics® technology. The company focuses on creating orally available drugs for diseases such as cancer, autoimmune disorders, and fibrosis, aiming to transform undruggable PPIs into druggable targets.
Average Trading Volume: 1,156,946
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.64B
Find detailed analytics on 206A stock on TipRanks’ Stock Analysis page.